Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

Posted by Brenda Bartman on Oct 1st, 2026

Shares of Vor Biopharma Inc. (NASDAQ:VOR – Get Free Report) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $41.71.

A number of brokerages have issued reports on VOR. Wedbush raised their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings upgraded shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th.

Read Our Latest Analysis on VOR

Vor Biopharma Price Performance

NASDAQ:VOR opened at $19.08 on Monday. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $49.64. The business has a 50 day moving average price of $22.12 and a 200-day moving average price of $17.93.

Vor Biopharma (NASDAQ:VOR – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). As a group, research analysts forecast that Vor Biopharma will post -2.56 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP grew its position in shares of Vor Biopharma by 37.5% in the 2nd quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after buying an additional 10,071 shares during the last quarter. Braidwell LP raised its holdings in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Vor Biopharma during the second quarter valued at approximately $499,000. Bank of New York Mellon Corp bought a new position in shares of Vor Biopharma during the second quarter valued at approximately $1,799,000. Finally, Bank of America Corp DE lifted its stake in Vor Biopharma by 28,408.1% in the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after acquiring an additional 112,496 shares during the period. Institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

(Get Free Report)

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.